Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
10.1007/s11596-015-1433-2
- Author:
Chao-Lin LI
1
;
Lu-Jie ZHAO
;
Xin-Li ZHOU
;
Hui-Xiao WU
;
Jia-Jun ZHAO
Author Information
1. Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China, lcl1633@sina.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Clinical Trials as Topic;
Dipeptidyl-Peptidase IV Inhibitors;
pharmacology;
therapeutic use;
Glucagon-Like Peptide 1;
agonists;
Humans;
Hypoglycemic Agents;
pharmacology;
therapeutic use;
Lipid Metabolism;
drug effects;
Non-alcoholic Fatty Liver Disease;
drug therapy;
metabolism;
Triglycerides;
metabolism
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(3):333-336
- CountryChina
- Language:English
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease and it represents the hepatic manifestation of metabolic syndrome, which includes type 2 diabetes mellitus (T2DM), dyslipidemia, central obesity and hypertension. Glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors were widely used to treat T2DM. These agents improve glycemic control, promote weight loss and improve lipid metabolism. Recent studies have demonstrated that the GLP-1 receptor (GLP-1R) is present and functional in human and rat hepatocytes. In this review, we present data from animal researches and human clinical studies that showed GLP-1 analogues and DPP-4 inhibitors can decrease hepatic triglyceride (TG) content and improve hepatic steatosis, although some effects could be a result of improvements in metabolic parameters. Multiple hepatocyte signal transduction pathways and mRNA from key enzymes in fatty acid metabolism appear to be activated by GLP-1 and its analogues. Thus, the data support the need for more rigorous prospective clinical trials to further investigate the potential of incretin therapies to treat patients with NAFLD.
